Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900560 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
A Phase 2 study, sponsored by Translational Research in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02900560: Clinical Trial Phase 2 study, sponsored by Translational Research in Oncology.
NCT02900560 is a Phase 2 study that was terminated before completion, run by Translational Research in Oncology. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02900560, a Phase 2 study, was terminated before completion, sponsored by Translational Research in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
Primary Outcome
Safety evaluation: number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency, severity and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG CC-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 2 |
Why NCT02900560 stopped before completion
NCT02900560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02900560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02900560 about?
NCT02900560 is a clinical study titled "Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer". The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
What is the current status of trial NCT02900560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-12-20. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT02900560?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CC-486 (DRUG).
Who is sponsoring clinical trial NCT02900560?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02900560's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI